Floatz logo

Ublituximab

Recurrent Splenic Marginal Zone Lymphoma

Yazeed Sawalhamonoclonal_antibodyPhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the Recurrent Splenic Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BB
Zanubrutinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Ublituximab is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
72 / 100
View asset →
marginal zone lymphomaDormant
B
Indicative ·
57 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →